AU2001273406A1 - Clostridial toxin derivatives and methods for treating pain - Google Patents

Clostridial toxin derivatives and methods for treating pain

Info

Publication number
AU2001273406A1
AU2001273406A1 AU2001273406A AU7340601A AU2001273406A1 AU 2001273406 A1 AU2001273406 A1 AU 2001273406A1 AU 2001273406 A AU2001273406 A AU 2001273406A AU 7340601 A AU7340601 A AU 7340601A AU 2001273406 A1 AU2001273406 A1 AU 2001273406A1
Authority
AU
Australia
Prior art keywords
methods
clostridial toxin
treating pain
toxin derivatives
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273406A
Inventor
Stephen Donovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of AU2001273406A1 publication Critical patent/AU2001273406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001273406A 2000-07-25 2001-07-12 Clostridial toxin derivatives and methods for treating pain Abandoned AU2001273406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/625,098 2000-07-25
US09/625,098 US6641820B1 (en) 2000-01-19 2000-07-25 Clostridial toxin derivatives and methods to treat pain
PCT/US2001/021984 WO2002007759A2 (en) 2000-07-25 2001-07-12 Clostridial toxin derivatives and methods for treating pain

Publications (1)

Publication Number Publication Date
AU2001273406A1 true AU2001273406A1 (en) 2002-02-05

Family

ID=24504575

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273406A Abandoned AU2001273406A1 (en) 2000-07-25 2001-07-12 Clostridial toxin derivatives and methods for treating pain

Country Status (4)

Country Link
US (1) US6641820B1 (en)
AR (1) AR030254A1 (en)
AU (1) AU2001273406A1 (en)
WO (1) WO2002007759A2 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) * 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
WO2001014570A1 (en) 1999-08-25 2001-03-01 Allergan Sales, Inc. Activatable recombinant neurotoxins
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7138127B1 (en) * 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
US20070048335A1 (en) * 2000-12-29 2007-03-01 Allergan, Inc. Methods for treating pain and hyperhidrosis
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
ZA200506715B (en) * 2003-03-06 2007-05-30 Botulinum Toxin Res Ass Inc Treatment of sinusitis related chronic facial pain and headache with botulinum toxin
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004035606A1 (en) * 2004-07-22 2006-03-30 Biotecon Therapeutics Gmbh Carrier for drugs for obtaining oral bioavailability
US7892565B2 (en) 2004-09-01 2011-02-22 Allergan, Inc. Degradable clostridial toxins
EP2985034A1 (en) 2004-09-23 2016-02-17 Toxcure, Inc. Treating neoplasms with neurotoxin
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
WO2006059093A2 (en) * 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
EP1861419B1 (en) 2005-03-15 2011-06-29 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8021859B2 (en) * 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP2214696A1 (en) * 2007-10-23 2010-08-11 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
ES2356883B1 (en) * 2008-07-24 2012-02-22 Bcn Peptides, S.A. COMPOSITION FOR THE TREATMENT OF PAIN AND / OR INFLAMMATION.
AU2011315962B2 (en) 2010-10-14 2016-06-02 Allergan, Inc. Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
WO2012174123A1 (en) 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
US20130171122A1 (en) * 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
ES2424294B1 (en) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails
MX356343B (en) 2012-04-13 2018-05-23 Lubrizol Advanced Mat Inc Compounds which inhibit neuronal exocytosis (ii).
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
WO2014100019A1 (en) 2012-12-18 2014-06-26 Allergan, Inc. Prophylactic treatment of herpes recurrence
US9447405B2 (en) 2013-03-08 2016-09-20 Wisconsin Alumni Research Foundation Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
CA2907800A1 (en) 2013-03-22 2014-09-25 Lipotec S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
EP3822286A1 (en) 2015-01-09 2021-05-19 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
TW201814045A (en) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 Method for producing di-chain clostridial neurotoxins
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
CN111465352B (en) 2018-02-26 2024-04-12 益普生生物制药有限公司 Injection of non-cytotoxic proteases using ultrasound guidance
EP3796929A1 (en) * 2018-05-21 2021-03-31 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
WO2024069191A1 (en) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Clostridial neurotoxin for use in a treatment of bladder pain syndrome

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189426A (en) 1976-04-12 1980-02-19 Hoffmann-La Roche, Inc. Recombinant hormonal compositions and method
US4481139A (en) 1983-04-13 1984-11-06 Board Of Regents, The University Of Texas System Peptide antagonists of substance P
US4664911A (en) 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
JPS60248659A (en) 1984-05-25 1985-12-09 Microbial Chem Res Found 3(n-(mercaptoacyl))amino-4-arylbutyric acid derivative and analgesic containing said derivative as active component
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5410019A (en) 1987-09-24 1995-04-25 The Administrators Of The Tulane-Educational Fund Therapeutic peptides
EP0499990B1 (en) 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
ES2117050T3 (en) 1991-06-27 1998-08-01 Genelabs Tech Inc SCREENING TEST FOR THE DETECTION OF MOLECULES OF UNION TO DNA.
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
JP3122319B2 (en) * 1994-05-02 2001-01-09 アソシエーティド ユニバーシティーズ，インコーポレイティド Tin-117m-containing radiotherapeutic agent
PT1086702E (en) 1994-05-09 2005-08-31 William J Binder PRE-SYNAPTIC NEUROTOXINS FOR THE TREATMENT OF CABBAGE PAIN DUE TO ENXAQUECA
DK0760681T3 (en) 1994-05-31 2000-03-27 Allergan Inc Modification of clostridial toxins for use as transport proteins
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5846216A (en) 1995-04-06 1998-12-08 G & P Technologies, Inc. Mucous membrane infusor and method of use for dispensing medications
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6565870B1 (en) * 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors

Also Published As

Publication number Publication date
AR030254A1 (en) 2003-08-13
US6641820B1 (en) 2003-11-04
WO2002007759A3 (en) 2003-01-03
WO2002007759A2 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
AU2001227930A1 (en) Clostridial toxin derivatives and methods for treating pain
AU2001273406A1 (en) Clostridial toxin derivatives and methods for treating pain
AU2001265043A1 (en) Botulinum toxin implant
AU2001286419A1 (en) Endourethral device and method
AU2001234565A1 (en) System and method for user authentication
AU2001292836A1 (en) Endoscopic targeting method and system
AU3309300A (en) Hair treatment device and method
AU2001268564A1 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
AU2001237997A1 (en) Method and system for event-centric user profiling and targeting
AU2001232647A1 (en) Methods and devices for treating stuttering problems
AU5381399A (en) Hair treatment device and method
AU2271400A (en) Composition, kit, method and device for hair treatment
AU2001265967A1 (en) Cryptographic method and cryptographic device
AU2001214905A1 (en) Security device and method
AU2001279850A1 (en) Method and arrangement for studsystem
AU5838700A (en) Method for treating and preventing finger disorders
AU2001275127A1 (en) Method for treating alcohol intoxication and alcohol abuse
AU2001236601A1 (en) Methods and devices for remediation and fermentation
AU2002228663A1 (en) Microorganism neutralization device and method
AU2001229471A1 (en) Apparatus and method for hair treatment
AU2001218024A1 (en) Methods for treating and preventing alopecia
AU1923501A (en) Pyridinones to treat and prevent bacterial infections
AU2002211359A1 (en) Stem cell-based methods for preventing and treating tumor
AU2001292952A1 (en) Selective inactivation and copy-protection
AU4677601A (en) Keyless encryption system and method